Quantoom and MSK unite on personalised cancer therapies
Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002. Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More